J Korean Ophthalmol Soc > Volume 57(5); 2016 > Article
Journal of the Korean Ophthalmological Society 2016;57(5):734-741.
DOI: https://doi.org/10.3341/jkos.2016.57.5.734    Published online May 15, 2016.
Comparison of Therapeutic Effects of 3% Diquafosol Tetrasodium with Aging in Dry Eye.
Seok Jae Lee, Ho Yun Kim, Young Min Park, Jong Soo Lee
1Department of Ophthalmology, Pusan National University School of Medicine, Busan, Korea. jongsool@pusan.ac.kr
2Department of Ophthalmology, Gyeongsang National University School of Medicine, Jinju, Korea.
3Gyeongsang National University Changwon Hospital, Changwon, Korea.
연령에 따른 안구건조증의 3% 디쿠아포솔나트륨 점안 효능 비교
이석재1⋅김호윤1⋅박영민2,3⋅이종수1
부산대학교 의학전문대학원 안과학교실1, 경상대학교 의학전문대학원 안과학교실2, 창원 경상대학교병원3
Received: 28 January 2016   • Revised: 31 March 2016   • Accepted: 28 April 2016
Abstract
PURPOSE
The aim of this study was to evaluate the clinical effect of 3% diquafosol in dry eye patients aged around 60 years. METHODS: In total, 68 patients with dry eye syndrome were divided by age into 2 groups, Group I (29 patients, 29 eyes) under the age of 60 years and Group II (39 patients, 39 eyes) over the age of 60 years. To evaluate the effectiveness of 3% diquafosol, we measured the tear film break-up time (tBUT), performed the Schirmer I test, and used the corneal staining score as an objective indicator and the ocular surface disease index (OSDI) score as a subjective indicator at initial visit, 1 month, 2 months, and 4 months. RESULTS: Significant improvements in the tear film break-up time, Schirmer I test, and OSDI were observed at 1,2, and 4 months after treatment with 3% diquafosol tetrasodium in both dry eye groups, but significant difference in the corenal staining score were not observed (p > 0.05). There were statistically significant improvement between the 2 age groups in the tBUT at 1 month (p = 0.012), 2 months (p = 0.005), and 4 months (p = 0.005), and improvements in the Schirmer I test between the 2 age groups at 1 month (p = 0.015), 2 months (p = 0.005), and 4 months (p = 0.005) were also observed. But, there was no significant difference in the corneal staining score and OSDI score between the 2 groups at 1, 2, and 4 months (p > 0.05). CONCLUSIONS: Topical 3% diquafosol tetrasodium administration was shown to be an effective treatment to improve clinical symptoms and objective indicators in dry eye patients regardless of age, showing significant improvements in tBUT and the Schirmer I test under the age of 60.
Key Words: Aging;Diquafosol;Dry eye syndrome


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next